Project Grant R43TR003743
Award Date
3/1/22
Completion Date
8/31/23
Dollars Obligated
$675K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55902, USA
Similar Awards
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research to improve the efficiency of CRISPR gene editing in human pluripotent stem cells. The goal is to develop a novel carbon nanotube array technology that can efficiently transfer nucleic acids and proteins into these cells to enhance CRISPR-based gene editing and homology-directed recombination. The $275,045 award to Advanced Gene...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $364,167 to Villanova University to develop novel non-viral gene delivery methods for cell therapies. The key objectives are: The Bracaglia Lab will develop new polymeric gene delivery vehicles to improve the delivery of siRNAs and other payloads to T cells and hematopoietic stem cells (HSCs). Drs. Elmer and Huang will...
This $325,000 project grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) will support the development and testing of a new class of programmable, non-viral gene therapy carriers and cargo known as virus-inspired DNA origami (VIDO) vectors and repair templates. The project aims to demonstrate that VIDO vectors can effectively encapsulate and co-deliver CRISPR-Cas9 gene editing agents and repair...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $307,091 to Aleutian Therapeutics, Inc. to develop immune evasive strategies for allogeneic cell replacement therapies. The goal is to use gene editing of pluripotent stem cells to enable stem cell-derived cell therapies to be transplanted without the need for immunosuppressive drugs. The Phase I research will...
This $298,530 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of recombinant protein "epigenetic editor biologics" that can modulate gene expression without altering DNA sequence. The project aims to characterize and compare two different protein designs - one using zinc finger proteins and the other using nuclease-null dCas9 - that target and demethylate...
This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...
This federal Project Grant award of $207,900 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286) supports research to develop a synthetic three-cell immunotherapy system. The goal is to engineer T cells, natural killer (NK) cells, and macrophages to express chimeric antigen receptors (CARs) and synthetic cytokine receptors (SCRs) in order to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $769,737 to Yale University to develop capsid-engineered adeno-associated viral (AAV) vectors that can specifically target and deliver gene therapies to human T cells and myeloid cells. The goal is to use these AAV vectors to deliver a designer recombinase called BREC1, which can eliminate HIV provirus integrated in...
This National Institutes of Health (NIH) grant, funded through the Cardiovascular Diseases Research program (CFDA 93.837), provides $486,291 to Rutgers University-Camden from February 1, 2025 to January 31, 2028 to develop novel nucleic acid nanoparticle technology for efficiently delivering the CRISPR/Cas9 gene editing system into hematopoietic stem cells. The goal is to enhance the precision and efficacy of genome editing in hematopoietic stem cells to treat genetic blood disorders like sickle...